Prediction of the structural interface between fibroblast growth factor23 and Burosumab using alanine scanning and molecular docking. Kanhasut K, Tharakaraman K, Ruchirawat M, Satayavivad J, Fuangthong M, Sasisekharan R. Sci Rep. 2022 Aug 30;12(1):14754.

30 Aug 2022
0

Prediction of the structural interface between fibroblast growth factor23 and Burosumab using alanine scanning and molecular docking.

Kanhasut K, Tharakaraman K, Ruchirawat M, Satayavivad J, Fuangthong M, Sasisekharan R.

Sci Rep. 2022 Aug 30;12(1):14754.

Tags

Share this

Related Posts

Efficacy of Andrographis paniculata extract treatment in mild to moderate COVID-19 patients being treated with favipiravir: A double-blind, randomized, placebo-controlled study (APFaVi trial)
Oncogenic roles of serine-threonine kinase receptor-associated protein (STRAP) in osteosarcoma. Pruksakorn D, Klangjorhor J, Lirdprapamongkol K, Teeyakasem P, Sungngam P, Chaiyawat P, Phanphaisarn A, Settakorn J, Srisomsap C*. Cancer Chemother Pharmacol. 2018 Dec;82(6):1039-1047.

Recent Posts